Fluorinated pyrrolidines and piperidines incorporating tertiary benzenesulfonamide moieties are selective carbonic anhydrase II inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 30, Issue 5, 2015, Pages 737-745

  Le Darz, Alexandre ^a,b   Mingot, Agnès ^b   Bouazza, Fodil ^a   Castelli, Ugo ^b   Karam, Omar ^a   Tanc, Muhammet ^c   Supuran, Claudiu T ^c   Thibaudeau, Sébastien ^b  

^a AtrtMolecule   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase; fluorine; selectivity; superacid; tertiary benzenesulfonamides

Indexed keywords

1 (4 AMINOBENZENESULFONYL) 2 (FLUOROETHYL)PYRROLIDINE; 1 (4 AMINOBENZENESULFONYL) 2 ETHYLPYRROLIDINE; 1 (4 AMINOBENZENESULFONYL) 2 VINYLPYRROLIDINE; 1 (4 NOSYL) 1,2,5,6 TETRAHYDROPYRIDINE; 1 (4 NOSYL) 2 (2 CHLOROFLUOROETHYL)PYRROLIDINE; 1 (4 NOSYL) 2 (CHLORO 2 FLUOROETHYL)PYRROLIDINE; 1 (4 NOSYL) 2 (FLUOROETHYL)PYRROLIDINE; 1 (4 NOSYL) 2 VINYLPYRROLIDINE; 1 (4 NOSYL) 4 CHLORO 3 FLUOROPIPERIDINE; 1 (4 NOSYL) 4 METHANESULFONATEPIPERIDINE; 1 (4 NOSYL)PIPERIDINE 4 OL; 1 (4 NOSYL)PYRROLIDINE 2 CARBALDEHYDE; BENZENESULFONAMIDE DERIVATIVE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; METHYL 1 (4 NOSYL)PYRROLIDINE 2 CARBOXYLATE; N (4 NOSYL) 3 CHLORO 4 FLUOROPIPERIDINE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; BENZENESULFONAMIDE; SULFONAMIDE;

ARTICLE; BINDING AFFINITY; CYTOSOL; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORINATION; HYDROGENATION; PRIORITY JOURNAL; WITTIG REACTION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; PIPERIDINES; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84940757919     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2014.963072     Document Type: Article

References (57)

1. Krishnamurthy VM, Kaufman GK, Urbach, AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008;108:946-1051.
2. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3:1165-80.
3. Supuran CT. Carbonic anhydrases as drug targets: general presentation. In: Supuran CT, Winum JY, eds. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken (NJ): Wiley; 2009:15-38.
4. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discovery 2008;7:168-81.
5. Winum JY, Rami M, Scozzafava A, et al. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445-63.
6. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2008;23:146-89.
7. Winum JY, Supuran CT. Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2014;18:1-4.
8. Supuran CT, Casini A, Scozzafava A. Development of sulfonamide carbonic anhydrase inhibitors. In: Supuran CT, Scozzafava A, Conway J, eds. Carbonic anhydrase: its inhibitors and activators. Boca Raton (FL): CRC Press; 2004:67-147.
9. Chohan ZH, Scozzafava A, Supuran CT. Zinc complexes of benzothiazole-derived Schiff bases with antibacterial activity. J Enzyme Inhib Med Chem 2003;18:259-63.
10. Supuran CT. Structure-bases drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759-72.
11. Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. Expert Opin Ther Pat 2013;23: 693-704.
12. Swenson ER. Safety of carbonic anhydrase inhibitors. Expert Opin Drug Saf 2014;13:459-72.
13. Supuran CT, Mincione F, Scozzafava A, et al. Metal complexes of heterocyclic sulfonamides: a new class of strong topical intraocular pressure-lowering agents with potential use as antiglaucoma drugs. Eur J Med Chem 1998;33:247-54.
14. Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012; 112:4421-68.
15. Wilkinson BL, Bornaghi LF, Houston TA, et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IX with triazole-linked O-glycosides of benzene sulfonamides. J Med Chem 2007;50: 1651-7.
16. Chohan ZH, Scozzafava A, Supuran CT. Unsymmetrical 1,1' - disubstituted ferrocenes: synthesis of Co(ii), Cu(ii), Ni(ii) and Zn(ii) chelates of ferrocenyl-1-thiadiazolo-1' -tetrazole, -1-thiadiazolo-1' - triazole and -1-tetrazolo-1' -triazole with antimicrobial properties. J Enzyme Inhib Med Chem 2002;17:261-6.
17. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767-77.
18. McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent development in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012;3:84-97.
19. Guler OO, De Simone G, Supuran CT. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem 2010;17:1516-26.
20. Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem 2013;56:293-300.
21. Ceruso M, Bragagni M, AlOthman Z, et al. New series of sulfonamides containing amino acid moiety act as a effective and selective inhibitors of tumor-associated carbonic anhydrase XII. J Enzyme Inhib Med Chem 2014;4:1-5.
22. 5. Chem Commun 2007:3198-200.
23. Vardelle E, Gamba-Sanchez D, Martin-Mingot A, et al. Cyclisation/fluorination of nitrogen containing dienes in superacid HF-SbF5: a new route to 3- and 4-fluoropiperidines. Chem Commun 2008: 1473-5.
24. 5 and synthesis of benzofused sultams. Org Lett 2010;12:868-71.
25. Compain G, Martin-Mingot A, Frapper G, et al. Anti-Markovnikov additions to N-allylic derivatives involving ammonium-carbenium superelectrophiles. Chem Commun 2012;48:5877-9.
26. Compain G, Jouvin K, Martin-Mingot A, et al. Stereoselective hydrofluorination of ynamides: a straightforward synthesis of novel α-fluoroenamides. Chem Commun 2012;48:5196-8.
27. Métayer B, Mingot A, Vullo D, et al. New superacid synthesized (fluorinated) tertiary benzenesulfonamides acting as selective hCA IX inhibitors: toward a new mode of carbonic anhydrase inhibition by sulfonamides. Chem Commun 2013;49:6015-17.
28. Métayer B, Mingot A, Vullo D, et al. Superacid synthesized tertiary benzenesulfonamides and benzofuzed sultams act as selective hCA IX inhibitors: toward understanding a new mode of inhibition by tertiary sulfonamides. Org Biomol Chem 2013;43:7540-9.
29. Compain G, Martin-Mingot A, Maresca A, et al. Superacid synthesis of halogen containing N-substituted-4-aminobenzene sulfonamides: new selective tumor-associated carbonic anhydrase inhibitors. Bioorg Med Chem 2013;21:1555-63.
30. Maresca A, Scozzafava A, Supuran CT. 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett 2010;20:7255-8.
31. Maresca A, Supuran CT. Coumarins incorporating hydroxyl- and chloro-moities selectively inhibit the transmembrane tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med Chem Lett 2010;20:4511-14.
32. Grandane A, Tanc M, Zalubovskis R, Supuran CT. Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem 2014;22:1522-8.
33. Lau J, Pan J, Zhang Z, et al. Synthesis and evaluation of (18)F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography. Bioorg Med Chem Lett 2014;24:3064-8.
34. D'Ascenzio M, Carradori S, De Monte C, et al. Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII. Bioorg Med Chem 2014;22:1821-31.
35. Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-62.
36. Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accomodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010;53:850-4.
37. Biswas S, Aggarwal M, Güzel Ö, et al. Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to different binding in the active site of the cytosolic human carbonic anhydrase isoforms. Bioorg Med Chem 2011;19: 3732-8.
38. Abbate F, Coetzee A, Casini A, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg Med Chem Lett 2004; 14:337-41.
39. Abbate F, Casini A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide: implications for the drug design of fluorinated inhibitors. J Enzyme Inhib Med Chem 2003;18:303-8.
40. Begue J-P, Bonnet-Delpon D. Bioorganic and medicinal chemistry of fluorine. Hoboken (NJ): Wiley; 2008.
41. Wang J, Sanchez-Rosello M, Acena JL, et al. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011). Chem Rev 2014;114:2432-506.
42. Morgenthaler M, Schweiser E, Hoffman-Röder A, et al. Predicting and tuning physiochemical properties in lead optimization: amine basicities. Chem Med Chem 2007;2:1100-15.
43. Müller K, Faeh C, Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science 2007;317:1881-6.
44. Böhm H-J, Banner D, Bendels S, et al. Fluorine in medicinal chemistry. Chem Bio Chem 2004;5:637-43.
45. Hu X-G, Hunter L. Stereoselectively fluorinated N-heterocycles: a brief survey. Beilstein J Org Chem 2013;9:2696-708.
46. Hunter L. The C-F bond as a conformational tool in organic and biological chemistry. Beilstein J Org Chem 2010;6:38.
47. c receptor. Chem Commun 2012;48:829-31.
48. Ceruso M, Vullo D, Scozzafava A, Supuran CT. Sulfonamides incorporating fluorine and 1,3,5-triazine moieties are effective inhibitors of three β-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2014;25:686-9.
49. Khalifah RG. Carbon dioxide hydratation activity of carbonic anhydrase: kinetics of alkylated anhydrases B and C from humans. J Biol Chem 1971;246:2561-73.
50. Rami M, Maresca A, Smaine F-Z, et al. Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem Lett 2011;21:2975-9.
51. Capkauskaite E, Baranauskiene L, Golovenko D, et al. Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII. Bioorg Med Chem 2010;18:7357-64.
52. Mader P, Brynda J, Gitto R, et al. Structural basis for the interaction between carbonic anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides. J Med Chem 2011;54:2522-6.
53. Mincione F, Benedini F, Biondi S, et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216-21 .
54. Bertucci A, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. Bioorg Med Chem Lett 2011;21:710-14.
55. Hen N, Bialer M, Yagen B, et al. Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. J Med Chem 2011;54: 3977-81.
56. Botrè F, Botrè C, Podestà E, et al. Effect of anti-carbonic anhydrase antibodies on carbonic anhydrases I and II. Clin Chem 2003;49: 1221-3.
57. Bosley TM, Salih MA, Alorainy IA, et al. The neurology of carbonic anhydrase type II deficiency syndrome. Brain 2011;134: 3499-512.